Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate Other stock markets 08:50:52 2024-09-16 am EDT			5-day change	1st Jan Change
34.04 ^EUR	-1.38%		+1.52%	+21.62%

Sep. 13	A central bank and it's off again?
Sep. 13	JPMorgan Upgrades Fresenius to Overweight, Lifts PT	MT

Fresenius beats Q2 expectations on strong unit performance, cost savings

July 31, 2024 at 01:16 am EDT

(Reuters) - German healthcare group Fresenius beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings.

It reported earnings before interests and taxes (EBIT) of 660 million euros ($714 million), up 16% from a year ago.

Analysts were expecting EBIT of 636 million euros, according to a consensus of forecasts from Vara Research.

($1 = 0.9239 euros)

(Reporting by Bartosz Dabrowski in Gdansk; Editing by Varun H K)

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	FRESENIUS MEDICAL CARE AG	37.09 EUR	-1.59%	+3.12%	12.26B
	FRESENIUS SE & CO. KGAA	34.04 EUR	-1.38%	+1.52%	21.55B

Latest news about Fresenius SE & Co. KGaA

A central bank and it's off again?	Sep. 13
JPMorgan Upgrades Fresenius to Overweight, Lifts PT	Sep. 13	MT
Goldman raises target for Fresenius SE to 38 euros - 'Neutral'	Sep. 13	DP
FRESENIUS SE : Goldman Sachs sticks Neutral	Sep. 13	ZD
Fresenius at high since May 2022 after JPMorgan recommendation	Sep. 13	DP
JPMorgan raises Fresenius SE to 'Overweight' - Target 40.10 euros	Sep. 13	DP
FRESENIUS SE : JP Morgan gives a Buy rating	Sep. 13	ZD
FRESENIUS SE : Receives a Buy rating from Berenberg	Sep. 11	ZD
Hospitals warn of service restrictions	Sep. 09	DP
FRESENIUS SE : DZ Bank reaffirms its Buy rating	Sep. 02	ZD
Medical service presents annual statistics on medical errors	Aug. 22	DP
Shelly Group Co-CEO Exits Role as Managing Director of Shelly DACH GmbH	Aug. 20	MT
Lack of blood donations: Reserves almost exhausted	Aug. 17	DP
FRESENIUS SE : Jefferies remains its Buy rating	Aug. 08	ZD
FRESENIUS SE : Receives a Buy rating from Barclays	Aug. 01	ZD
FRESENIUS SE : Warburg Research keeps its Buy rating	Aug. 01	ZD
FRESENIUS : Lots of positives for a strong Q2	Aug. 01
Frankfurt equities close: Cautious optimism ahead of US interest rate decision	Jul. 31	DP
Global markets live: Airbus, HSBC, Boeing, Microsoft, Starbucks...	Jul. 31
Transcript : Fresenius SE & Co. KGaA, Q2 2024 Earnings Call, Jul 31, 2024	Jul. 31
Barclays reads 'Overweight' for Fresenius SE - Target 36.50 euros	Jul. 31	DP
FRESENIUS SE : Gets a Neutral rating from Goldman Sachs	Jul. 31	ZD
FRESENIUS SE : Jefferies remains its Buy rating	Jul. 31	ZD
FRESENIUS SE : Warburg Research reaffirms its Buy rating	Jul. 31	ZD
FRESENIUS SE : Deutsche Bank reaffirms its Buy rating	Jul. 31	ZD

Chart Fresenius SE & Co. KGaA

Duration

Period

More charts

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).

Employees

175,771

Sector

Healthcare Facilities & Services

Calendar

2024-11-05 - Q3 2024 Earnings Call

More about the company